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ABSTRACT (WC = 250) 
Background: Antiplatelet therapies, including prasugrel, are a cornerstone in the treatment of 
ST-elevation myocardial infarction (STEMI) but they are associated with a risk of bleeding. 
This risk has been evaluated in randomized trials but few data are known in real-world 
patients. 
Methods: Consecutive patients with STEMI were recruited over one year. Follow-up was 
done at three months and at one year to evaluate the safety of prasugrel from hospital 
discharge to the anniversary date of the STEMI. The primary outcome was the occurrence of 
any major bleeding according to Bleeding Academic Research Consortium (BARC) 3 or 5 
definitions or minor bleeding according to BARC 2 definition. 
Results: 1083 patients were recruited. Compared to patients treated with aspirin + 
clopidogrel, patients treated with aspirin + prasugrel had less BARC 3 or 5 bleeding (9 
patients, 1.8% versus 2 patients 0.4%, p=0.04) but more BARC 2 bleeding (20 patients, 4.0% 
versus 45 patients, 9.3%, p<0.001). Patients’ baseline characteristics treated with prasugrel 
were different compared to those in patients treated with clopidogrel because they were 
carefully selected (younger patients, higher body max index, less history of stroke). This 
selection leads to a better control of bleeding risk. In the overall population, rates of in-
hospital major bleeding and out-of-hospital major bleeding were 2.6% (n = 28) and 1.3% (n = 
13) respectively.  
Conclusion: Major bleeding, particularly out-of-hospital bleeding, in patients treated with 
prasugrel is low within one year after a STEMI. An accurate selection of patient candidates 
for prasugrel reduces the risk of bleeding. 
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RESUME 
Introduction: Les traitements antiplaquettaires, dont le Prasugrel, sont un élément majeur 
dans le traitement du syndrome coronarien aigu avec sus-décalage du segment ST (SCA ST+) 
mais entraînent un sur-risque hémorragique. Ce risque a été évalué dans des essais cliniques 
randomisés mais il existe peu de données dans la « vraie vie ». 
Méthodes : Les patients avec SCA ST+ ont été recrutés pendant un an et le suivi a été 
effectué, par téléphone, 3 mois et 1 an après le SCA ST+ afin d’évaluer la sécurité du 
Prasugrel, en particulier pendant la période post-hospitalière. Le critère d’évènement principal 
était la survenue d’un évènement hémorragique majeur défini selon la classification Bleeding 
Academic Research Consortium (BARC) 3 ou 5 ou d’un évènement hémorragique mineur 
défini selon la classification BARC 2. 
Résultats : 1083 patients ont été recrutés. Les patients traités par Aspirine + Clopidogrel 
avaient moins de saignements BARC 3 ou 5 que les patients traités par Aspirine + Prasugrel 
(9 patients, 1,8% versus 2 patients, 0,4%, p = 0,04) mais ils avaient plus de saignements 
BARC 2 (20 patients, 4,0% versus 45 patients, 9,3%, p<0.001). Les caractéristiques des 
patients traités par Prasugrel étaient différentes des patients traités par Clopidogrel car la 
sélection était attentive : patients plus jeunes, indice de masse corporelle plus élevé, moins 
d’antécédent d’accident vasculaire cérébral. Cette sélection a permis un meilleur contrôle du 
risque hémorragique. Les pourcentages de saignement intra-hospitalier majeur et de 
saignement extra-hospitalier majeur étaient respectivement de 2,6% (n = 28) et 1,3% (n = 13). 
Conclusion : Les saignements majeurs, en particulier extra-hospitaliers, sont peu fréquents 
chez les patients traités par Prasugrel dans l’année qui suit un SCA ST+. Une sélection 
attentive des patients pouvant bénéficier du Prasugrel permet une diminution de ce risque. 
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ABBREVATIONS LIST 
 
ACS   Acute coronary syndrome 
BARC   Bleeding Academic Research Consortium 
CABG   Coronary artery bypass grafting 
ENT   Ear, nose and throat 
GRACE   Global Registry of Acute Coronary Events 
MACE  Major adverse cardiac event 
PCI   Percutaneous coronary intervention 
STEMI  ST-segment elevation myocardial infarction 
TIMI   Thrombolysis in Myocardial Infarction 
TRITON-TIMI Trial to Assess Improvement in Therapeutic Outcomes by Optimizing 
Platelet Inhibition with Prasugrel-TIMI 
VKA   Vitamin K antagonist 
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INTRODUCTION 
 
Cardiovascular diseases, including acute myocardial infarction, are currently one of the 
leading causes of death in Western countries. Medical therapies focus on anticoagulation and 
platelet inhibition to reduce the risk of thrombotic events and improve ischemic outcomes of 
patients with ST-segment elevation myocardial infarction (STEMI). These, coupled with early 
use of cardiac catheterization and revascularization, reduce the rate of death and re-infarction 
but carry a bleeding risk. Indeed, bleeding is the most common non-cardiac complication of 
antithrombotic therapy in acute coronary syndromes (ACS) and has been associated with 
adverse outcomes, including myocardial infarction, stroke and death [1,2]. Thus, clinicians 
must balance antithrombotic treatment efficacy in preventing ischemic events with the need to 
minimize the risk of serious bleeding complications. Bleeding is even more frequent when 
percutaneous coronary intervention (PCI) is performed in the context of acute STEMI, when 
compared to bleeding complicating an elective procedure [3]. Several new antiplatelet 
therapies, including prasugrel, have been evaluated in randomized trials. They reduce the 
ischemic risk but are associated with an increased risk of major bleeding. In patients with 
STEMI undergoing PCI, prasugrel is more effective than clopidogrel for prevention of 
ischemic events, without excess in bleeding [4]. However, there are few data about the safety 
of new antiplatelet agents and bleeding risk within one year after a STEMI in real-world 
patients [5,6,7]. The Bleeding and Myocardial Infarction Study (Bleed-MI study) sought to 
evaluate the safety of prasugrel in real-world patients with STEMI, from hospital discharge to 
the anniversary date of the STEMI. Safety was assessed by analyzing the out-of-hospital 
bleeding. 
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METHODS 
 
Study patients 
Patients were included, from April 1, 2011 to March 31, 2012, if they had a STEMI 
and were hospitalized in any of the 9 primary percutaneous intervention centers in Brittany, 
France, within 24 hours after the onset of symptoms. There was no exclusion criterion. Data 
were recorded in the ORBI-registry. This registry was approved by the Commission Nationale 
Informatique et Liberté. All patients were informed of the aims of the study and could request 
to be excluded. The follow-up interviews were conducted by research nurses at three months 
and at one year by telephone. The follow-up questionnaire permitted key information about 
antiplatelet and anticoagulation therapies, medical treatment, and occurrence of bleeding or 
ischemic events. In case of bleeding or ischemic events, the hospitalization reports and all 
medical examination results (e.g., blood test, medical imaging, etc) were recovered so all data 
were centralized. Patients in whom follow-up data were lacking were considered lost to 
follow-up. 
Definitions 
The Bleeding Academic Research Consortium (BARC) [8] was used to define 
bleeding events occurring within one year after a STEMI. BARC 3 or 5 bleeding were 
considered major bleedings; BARC 2 bleeding were considered minor bleedings. BARC 1 
bleedings were not collected because they do not require treatment by a healthcare 
professional. Thus, there collection would not have been exhaustive. Coronary artery bypass 
graft (CABG) – related bleeding (BARC 4 bleedings) were not analyzed. Bleeding rates were 
also defined according to Thrombolysis In Myocardial Infarction (TIMI) definitions [9]. 
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Cardiovascular death was any death due to a new ACS, severe cardiac arrhythmia, refractory 
congestive heart failure, cardiogenic shock, stroke, sudden death or unwitnessed death. Acute 
myocardial infarction was defined in accordance with the universal definition of myocardial 
infarction proposed in 2012 [10]. Evaluation for stent thrombosis was performed according to 
the Academic Research Consortium criteria [11]. 
Study outcomes 
The primary outcome was the occurrence of any minor or major bleeding between 
discharge and the end of the follow-up at one year. A ―bleeding events‖ committee validated, 
classified, and located the site of each bleeding event, thanks to the phone interviews, the 
hospitalization reports and the medical examination results. Pre-specified secondary outcomes 
included in-hospital major bleeding and rates of premature stops (transitory or not) of any 
antithrombotic treatment after a bleeding complication. The rates of major adverse cardiac 
events (MACE), including cardiovascular death, nonfatal STEMI, nonfatal stroke, and stent 
thrombosis were calculated. 
Statistical methods 
Data description started with displaying the number of patients having hemorrhage or 
who were censored with no event at the date of point (12 months after myocardial infarction). 
Descriptive statistics included mean and standard deviation for normally distributed 
continuous variables, median and interquartile range otherwise and number and percentage 
for categorical variables. Comparisons according to dual antiplatelet regimen on discharge 
used chi-square or Fisher exact test for categorical variables and Student’s t test or Wilcoxon 
test for continuous variables. For the main outcome, a survival analysis was used. Only one 
event per subject could occur in the analysis.  
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First, univariate (marginal) Wald test statistics using the Cox model were performed 
for each covariate. Then, multivariate modeling was completed with a Cox proportional 
hazards model that contained all covariates significantly associated in the univariate analyses 
at the P = 0.15 level. We used a hand-made stepwise backward elimination process: following 
the fit of the multivariable model, we used the P values from the Wald tests of the individual 
coefficients to identify covariates that might be deleted from the model. The linearity of the 
relationship between continuous covariates was not rejected except for hematocrit value when 
considering death; a cutoff at 37.4% was identified from martingale residuals analysis. In 
addition, the graphical and numerical methods derived from cumulative sums of martingale 
residuals over follow-up times or covariate values of Lin, Wei, and Ying [12] were used for 
checking the proportional hazard assumption. For all statistical analyses, SAS version 9.3 
(SAS Institute, Cary, North Carolina) was used. 
 
RESULTS 
Study patients and in-hospital events 
1083 consecutive patients with STEMI from nine centers in Brittany were recruited 
from April 2011 through March 2012. No patient requested to be excluded. Follow-up 
occurred from July 1, 2011 to March 31, 2013. The baseline characteristics of the patients are 
summarized in Table 1. Coronary angiography was performed in 1060 patients (97.9%), with 
radial access in 564 patients (53.2%) and angioplasty was performed in 974 patients (89.9%); 
91.6% (n = 892) of stented patients received ≥1 stent, and 22.5% (n = 219) of stented patients 
had ≥1 drug- eluting stent. 2b3a inhibitors were used for 489 patients (45.2%). 
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In-hospital BARC 3 bleeding was observed in 28 patients (2.6%) and there was no in-
hospital BARC 5 bleeding. Among these 28 patients, bleeding was attributed to a vascular 
access site in 7 patients (25%). In-hospital BARC 2 bleedings were not recorded. Switches 
from prasugrel to clopidogrel concerned 48 patients (4.4%), mainly for precaution of use. 
Because of 51 in-hospital deaths (4.7%), 1032 patients were analyzed for follow-up. 
At discharge, 1021 patients (98.9%) were treated with aspirin, 513 patients (49.7%) were 
treated with clopidogrel, 484 patients (46.9%) were treated with prasugrel and 52 patients 
(5.0%) were treated with a vitamin K antagonist (VKA). Overall, 956 patients (92.6%) were 
treated with dual antiplatelet therapy alone and 32 patients (3.1%) were treated with a triple 
antithrombotic therapy (aspirin + clopidogrel + VKA or aspirin + prasugrel + VKA). Twenty-
three patients (2.2%) were treated with only one antiplatelet agent (aspirin: 19 patients; 
clopidogrel: 3 patients; prasugrel: 1 patient). Data were missing for 23 patients (2.2%). A total 
of 26 patients (2.5%) were lost to follow-up at the end of the follow-up period (Figure 1). 
Bleeding  
 An out-of-hospital major bleeding according to BARC 3 or 5 definitions occurred in 
13 patients out of 1006 (1.3%) (Table 2).  An out-of-hospital major bleeding according to 
TIMI definition occurred in 6 patients out of 1006 (0.6%). Total BARC 3 or 5 bleeding, 
including in-hospital bleeding, was observed in 41 patients (3.8%) and occurred during the 
first trimester in 33 patients (80.5% of major bleedings) (Figure 2). The most frequent out-of-
hospital BARC 3 or 5 bleeding sites were gastrointestinal- (n = 6) and cerebral sites (n = 4). 
The most frequent out-of-hospital BARC 2 bleeding sites were ENT- (n = 26), cutaneous- (n 
= 14) and gastrointestinal sites (n = 12) (Table 3). 
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 Patients treated with aspirin + prasugrel compared to patients treated with aspirin + 
clopidogrel had statistically significantly less BARC 3 or 5 bleeding (0.4% vs. 1.8%, 
respectively, p=0.04) but more BARC 2 bleeding (9.3% vs. 4.0%, respectively, p<0.001). 
Among the 988 patients treated with dual antiplatelet therapy, baseline characteristics of 
patients treated with prasugrel were different compared to those of patients treated with 
clopidogrel (Table 1). Patients treated with aspirin + prasugrel were more often male, 
younger, with a higher body max index, and with less history of arterial hypertension, stroke 
or transient ischemic attack. Patients treated with prasugrel were carefully selected: eight 
patients (1.7%) were aged ≥75 years among patients treated with prasugrel, while 193 patients 
(37.6%) were aged ≥75 years in the clopidogrel group. Thirteen patients (2.7%) weighed <60 
kg among patients treated with prasugrel, whereas it concerned 107 patients (20.8%) in the 
clopidogrel group. Five patients (1.0%) had a history of stroke or transient ischemic attack 
among patients treated with prasugrel, whereas it concerned 19 patients (3.7%) in the 
clopidogrel group. In the Bleed-MI study, the rate of major out-of-hospital bleeding was low 
so it reduced the statistical power for detecting any clinical and biological predictors of 
bleeding events.  
Antithrombotic agents 
 Among the 79 patients with out-of-hospital BARC 2, 3 or 5 bleeding, 25 patients were 
treated with aspirin + clopidogrel (5.2% of patients with this association), 45 with aspirin + 
prasugrel (9.5% of patients with this association), 2 with aspirin + VKA (14.3% of patients 
with this association), 4 with aspirin + clopidogrel + VKA (16% of patients with this 
association), 2 with aspirin + prasugrel + VKA (28.6% of patients with this association) and 1 
with aspirin alone (5.3% of patients with aspirin alone). Thereby, 7.3% of patients (70/956) 
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treated with 2 antiplatelet agents underwent out-of-hospital bleeding, 18.7% of patients (6/32) 
treated with 3 antithrombotic agents underwent out-of-hospital bleeding. Moreover, 0.9% of 
patients (9/956) treated with dual antiplatelet therapy alone underwent a BARC 3 or 5 out-of-
hospital bleed and 7.7% (4/52) of patients treated with a VKA underwent BARC 3 or 5 out-
of-hospital bleeding. Anticoagulant agents therefore had an important role in the occurrence 
of major bleeding events. 
Discontinuation of medication  
 Bleeding (BARC 2, 3 or 5) had led to temporary or definitive discontinuation of ≥ 1 
antithrombotic agent in 27 out of 79 patients who had bleeding. Among these patients, 
prasugrel was replaced by clopidogrel for 5 patients. The discontinuation was definitive for 20 
patients (74% of patients with discontinuation of treatment): aspirin in 2 patients, clopidogrel 
in 8, prasugrel in 8, VKA in 1, and prasugrel + VKA in 1 patient. The discontinuation was 
transient for 7 patients :  aspirin in 3 patients, clopidogrel in 1, aspirin + clopidogrel in 1, and 
VKA in 2 patients. The mean delay of antithrombotic agent discontinuation was 6.5 months 
(± 4.5). Antithrombotic agents were interrupted before month 6 in 13 patients (48.1%), after 
month 6 in 14 patients (51.9%), and beyond month 9 in 11 patients (40.7%). 
 The most frequent bleeding sites leading to treatment discontinuation were 
gastrointestinal (25.9%), ENT (25.9%) and cutaneous (25.9%). Interestingly, bleeding that led 
to discontinuation of medications was not major in most of cases. In fact, 74.1% of those 
bleeds were BARC 2, 14.8% BARC 3a, 3.7% BARC 3b, and 7.4% were BARC 3c. No 
ischemic event was observed after discontinuation of antithrombotic medications. There was 
no relation found between bleeding occurrence and increased risk of ischemic event. 
Predictive factors of death 
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Forty-four patients (4.4%) died from any cause during follow-up. From multivariable 
analysis, the factors independently associated with death included age (HR, 2.2; 95% CI, 1.6–
3.0; P < 0.001), signs of congestive heart failure on presentation (HR, 4.1; 95% CI, 2.1–8.1; P 
< 0.001) and baseline hematocrit ≤ 37.4% (HR, 0.3; 95% CI, 0.2–0.6; P < 0.001).  Although 
any BARC 3 or 5 bleedings predicted death in univariate analysis, they did not remain 
independent predictors of death after adjustment with other covariates. It was the same for 
sex, weight, body mass index, prior hypertension, prior coronary heart disease, prior chronic 
renal disease, baseline creatinine, and hospitalization duration. 
Out-of hospital ischemic events 
 The rate of out-of-hospital MACE among patients with BARC 2, 3 or 5 bleeding was 
7.6% (6 patients). There was no statistically significant difference compared to the entire 
population. Among all patients, the rate of out-of-hospital MACE was 6.1% (61 patients): 
death from cardiovascular causes occurred in 24 patients (2.4%), nonfatal MI in 10 (1.0%), 
nonfatal non-STEMI in 7 (0.7%), nonfatal stroke in 5 (0.5%), fatal stent thrombosis in 8 
(0.8%), and nonfatal stent thrombosis in 7 patients (0.7%). The rate of stent thrombosis was 
1.5%: 5 patients had a definite-, 5 patients had a probable-, and 5 patients had a possible stent 
thrombosis. 
 
DISCUSSION 
The Bleed-MI study allowed the evaluation of safety of prasugrel in non-selected 
STEMI patients in a real-world setting, according to the bleeding risk. This knowledge is 
crucial for the clinician who should choose the best antithrombotic treatment and its optimal 
duration according to the ischemic and bleeding risks. The final decision concerning an 
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individual patient must be made by the responsible physician taking into account the balance 
benefit/risk as recalled in the last European Society of Cardiology Guidelines for the 
management of STEMI [3]. 
 In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel-TIMI (TRITON-TIMI 38) [13], patients aged ≥75 years showed no 
net benefit from prasugrel and there were no statistically significant higher rates of non-
CABG-related TIMI major bleeding in the prasugrel group versus the clopidogrel group 
(4.3% vs. 3.3%, p=0.10). In the Bleed-MI study, patients treated with prasugrel compared to 
patients treated with clopidogrel had more BARC 2 bleeding but less BARC 3 or 5 bleeding. 
This low risk of major bleeding in prasugrel-treated patients in this real-life registry, despite 
frequent use, is reassuring and can be explained by the selection of patient candidates for 
prasugrel (lower bleeding risk patients). It means that the contraindications and the 
precautions for use of prasugrel are relevant. Moreover, it means that physicians are using the 
drug appropriately in appropriate candidates. Nevertheless, 33 patients (6.81% of patients 
treated with prasugrel) with contraindications or precautions for use of prasugrel received 
prasugrel in the study: 5 patients with history of stroke or TIA, 8 patients aged ≥75 years and 
13 patients weighing < 60 kg, 7 patients with concomitant use of VKA. 
Unlike many studies, we included non-selected patients, which make our results useful 
in real-world practice. Most studies include selected patients (patients undergoing PCI for 
STEMI for example). In the Bleed-MI study, coronary angiography was not performed for 22 
patients (2%) and no angioplasty was performed for 109 patients (10.1%). These patients are 
rarely studied in randomized trials. Moreover, we focused on out-of-hospital events: the in-
hospital bleeding, often related to procedural bleeding complications (PCI or CABG) should 
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be differentiated from out-of-hospital bleeding. The rate of out-of-hospital major bleeding 
within 1 year after a STEMI was low at 1.3% according to the BARC definition and 0.6% 
according to the TIMI definition. The rate of major out-of-hospital bleeding is particularly 
low in patients treated with prasugrel due to accurate selection of patients. The chronology of 
major bleeding is important due to its impact on the duration of antithrombotic treatment 
association in high bleeding risk patients. Bleeding can lead to a transitory or permanent 
discontinuation of one or more antithrombotic treatments, with the risk of stent thrombosis in 
stented patients and the risk of ischemic complications in all patients. In total, 68.3% of major 
bleedings occurred during the initial hospitalization. In a study published by Collet [14] in 
2004, 5.4% patients admitted for a suspected ACS had recently withdrawn antiplatelet agents, 
which was found to be an independent predictor of mortality and bleeding at 30 days. In the 
Bleed-MI study, out-of-hospital bleeding (BARC 2, 3 or 5) led to early discontinuation of any 
thrombotic agent (before 6 months) in only 13 patients (16.5% of out-of-hospital bleedings). 
Moreover, there was no ischemic event among the 27 patients who discontinued their 
treatment. Bleeding (including minor bleeding) must not be underestimated and should be 
systematically sought during the medical follow-up of patients after ACS since it would 
promote treatment compliance. 
 The reported rates of major bleedings at 9-12 months’ follow-up after ACS vary from 
2 to 6% [15,16,17,18]. In the Bleed-MI study, in-hospital and out-of-hospital major bleeding 
occurred in 3.8% according to BARC definition and 1.5% according to TIMI definition. In 
TRITON-TIMI 38 [13], the rate of non-CABG-related TIMI major bleeding at 15 months in 
the entire population was 2%. Considering only patients undergoing PCI for STEMI [4], the 
risk of non-CABG major bleeding was lower (1.1%), which is close to our rate of 1.5%. In the 
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PLATO study [15], the rate of non-CABG-related TIMI major bleedings at 12 months among 
patients with a STEMI was 2.2%. Considering the localization of bleedings in our study, the 
most frequent out-of-hospital major bleeding sites are gastrointestinal, but the most frequent 
out-of-hospital minor bleeding sites are ENT and cutaneous sites and the most severe out-of-
hospital bleeding sites are cerebral. In the Global Registry of Acute Coronary Events 
(GRACE) study [19], the most common life-threatening in-hospital bleeding complications 
were also gastrointestinal. 
 
LIMITATIONS  
As in any registry, this observational study has some limitations. For instance, 26 
patients (2.5%) were lost to follow-up. The follow-up was made by telephone contact at 3 
months and at 1 year but data collection was done by qualified hospital staff with directed 
questionnaires, which limits the loss of data. Moreover, BARC 1 bleedings were not collected 
because there collection would not have been exhaustive, due to the declaratory nature of data 
collection. Premature treatment cessation due to BARC 1 bleedings could then not have been 
analyzed. 
No patient was treated with Ticagrelor because this treatment was not yet available in 
Brittany during the study. 
According to an analysis from the TRITON-TIMI 38 study [20], independent 
predictors of non-CABG-related serious bleeding throughout 15 months were female sex, use 
of glycoprotein IIb/IIIa inhibitor, duration of intervention, age, assignment to prasugrel versus 
clopidogrel, STEMI, femoral access, creatinine clearance, hypercholesterolemia, and 
hypertension. In the Bleed-MI study, the low rate of major out-of-hospital bleedings reduced 
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the statistical power for detecting clinical and biological predictors of bleeding events. Any 
usual predictors of bleeding events could not be found and no statistical association between 
the occurrence of major bleeding and mortality was demonstrated. 
 
CONCLUSION 
Major bleeding rate, in patients treated with prasugrel after STEMI within one year 
after a STEMI is low when patients are carefully selected. The question remains of extending 
the prescription of new antiplatelet agents to a broader population of patients but with the risk 
of modifying the benefit-risk balance that we have documented in real world selected patients. 
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TABLES 
 
Table 1. Baseline Characteristics of the Patients 
 Population 
(n=1083) 
Aspirin + 
Clopidogrel 
(n = 505) 
Aspirin + 
Prasugrel 
(n = 483) 
p 
Median age – yr 62.7±14.0 67.3±14.2 55.9±10.2 <.0001 
Female sex - n (%) 282  (26.0) 171 (33.9) 67 (13.9) <.0001 
Median body weight - kg 75.5 ± 15.0 71.2±14.7 80.7±13.4 <.0001 
BMI - kg/m² 26.3 ± 4.3 25.4±4.3 27.2±4.0 <.0001 
Cardiovascular risk factor - n (%)     
       Habitual smoker 439 (40.5) 159 (31.7) 254 (52.6) <.0001 
       Arterial hypertension 460 (42.5) 252 (49.9) 150 (31.1) <.0001 
       Diabetes mellitus 147 (13.6) 72 (14.3) 59 (12.2) 0.3441 
Other medical history – n (%)     
       Stroke/AIT 34 (3.1) 20 (4.0) 5 (1.0) 0.0034 
       Chronic renal disease 23 (2.1) 15 (3.0) 5 (1.0) 0.0309 
       Gastroduodenal ulcer 34 (3.1) 11 (2.2) 7 (1.4) 0.3918 
Initial use of 2b3a inhibitors 489 (45.2) 233 (46.1) 233 (48.2) 0.51 
Bleeding- n (%)     
       Total  23 (4.6) 43 (8.9) 0.0110 
       BARC 2  15 (3.0) 42 (8.7) 0.0003 
       BARC 3  6 (1.2) 1 (0.2) 0.1246 
25 
 
 
 
       BARC 5  2 (0.4) 0 (0) 0.4998 
       BARC 3 + 5  8 (1.6) 1 (0.2) 0.0389 
 
BMI indicates body mass index; CABG, coronary artery bypass grafting ; PCI, percutaneous 
coronary intervention; TIA, Transient Ischemic Attack; BARC, Bleeding Academic Research 
Consortium. 
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Table 2. Chronology of Bleeding: In-hospital and Out-of-hospital Bleeding 
 In-hospital 
bleeding 
(n=1083) 
Out-of-hospital 
bleeding 
(n=1006) 
BARC definition- n (%)   
       BARC 2 bleeding Not collected 66 (6.6) 
       BARC 3 bleeding 28 (2.6) 11 (1.1) 
            BARC 3a 17 (1.6) 6 (0.6) 
            BARC 3b 9 (0.8) 3 (0.3) 
            BARC 3c  2 (0.2) 2 (0.2) 
       BARC 5 bleeding 0 (0) 2 (0.2) 
            BARC 5a 0 (0) 2 (0.2) 
            BARC 5b 0 (0) 0 (0) 
       BARC 3 or 5 bleeding 28 (2.6) 13 (1.3) 
TIMI definition- n (%)   
       TIMI major bleeding 10 (0.9) 6 (0.6) 
       TIMI major or minor bleeding 22 (2.0) 13 (1.3) 
BARC indicates Bleeding Academic Research Consortium; TIMI, Thrombolysis in 
Myocardial Infarction. 
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Table 3. Localization of out-of-hospital bleeding and vascular access 
 BARC- n Radial access- 
n (%) 
 BARC 2 BARC 3 BARC 5  
       Cutaneous 14 1 0 5 (33) 
       Gastrointestinal 12 6 0 13 (72) 
       Cerebral bleeding 0 2 2 0 (0) 
       ENT 26 0 0 15 (57) 
       Respiratory tract bleeding 5 0 0 2 (40) 
       Urinary tract bleeding 5 0 0 4 (80) 
       Others 4 2 0 3 (50) 
       Total 66 11 2 42 (53) 
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FIGURES 
 
 
Figure 1. Flow-Chart. STEMI indicates ST-segment elevation myocardial infarction. 
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Figure 2. Patients with BARC 3 or 5 Bleeding during the Follow-up Period. BARC indicates 
Bleeding Academic Research Consortium. 
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